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Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare
neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential dis-
ease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes).
We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-
rigid syndrome diagnosed as having PSP or MSA according to modiﬁed consensus diagnostic criteria were considered for
inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively
by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP
or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary
endpoint was survival. Secondary efﬁcacy outcomes were rates of disease progression assessed by functional measures. A total
of 767 patients were randomized and 760 qualiﬁed for the Intent to Treat (ITT) analysis, stratiﬁed at entry as PSP (362 patients)
or MSA (398 patients). Median follow-up was 1095 days (range 249–1095). During the study, 342 patients died and 112 brains
were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the
investigators’ assessment of diagnostic probability (point-biserial correlation: MSA rpb=0.93, P_0.0001; PSP, rpb = 0.95,
P_0.0001), and excellent predictive validity against histopathology [sensitivity and speciﬁcity (95% CI) for PSP 0.95 (0.88–
0.98) and 0.84 (0.77–0.87); and for MSA 0.96 (0.88–0.99) and 0.91 (0.86–0.93)]. There was no evidence of a drug effect on
survival in the PSP or MSA strata (3 year Kaplan–Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53,
MSA-placebo: 0.58; P=0.66 and P=0.48 by the log-rank test, respectively), or in the population as a whole (P=0.42, by the
stratiﬁed-log-rank test). Likewise, rate of progression was similar in both treatment groups. There were no unexpected adverse
effects of riluzole, and no signiﬁcant safety concerns. Riluzole did not have a signiﬁcant effect on survival or rate of functional
deterioration in PSP or MSA, although the study reached over 80% power to detect the hypothesized drug effect within strata.
The NNIPPS diagnostic criteria were consistent and valid. They can be used to distinguish between PSP and MSA with high
accuracy, and should facilitate research into these conditions relatively early in their evolution.
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Introduction
Progressive supranuclear palsy (PSP) and multiple system atrophy
(MSA) are disabling and fatal neurodegenerative disorders for
which no disease-modifying treatment is available. For the major-
ity of patients with PSP and MSA, many of whom present with
an atypical Parkinsonian or akinetic-rigid syndrome (‘Parkinson
plus disorder’) the course is one of relentless progression, increasing
disability and death with a median survival of 5–10 years from
onset of symptoms (Litvan et al., 1996a; Testa et al., 1996, 2001;
Ben-Shlomo et al., 1997; Schrag et al., 1999, 2008; Litvan, 2003;
Golbe and Ohman-Strickland, 2007).
PSP and MSA have similar prevalence rates estimated at 2–7
per 100000 person years (Golbe et al., 1988; Ben-Shlomo et al.,
1997; Bower et al., 1997; Schrag et al., 1999; Nath and Burn, 2000;
Nath et al., 2001; Vanacore et al., 2001a, b; Watanabe et al., 2002).
These are probably underestimates, however, because current diag-
nostic criteria are based on retrospective clinicopathological studies
(Litvan et al., 1996a, b, d, 2003; Litvan, 2003) and both delayed
diagnosis and mis-diagnosis are common. Although published con-
sensus diagnostic criteria are highly speciﬁc they are relatively insen-
sitive and a deﬁnite diagnosis can only be made through
histopathology (Litvan et al., 2003). Since it is likely that neuropro-
tective strategies are best tested at a relatively early stage of disease,
more sensitive diagnostic criteria are required for trials of potential
disease-modifying agents. Although PSP and MSA often present as
akinetic-rigid syndromes, each has distinctive pathological features.
In MSA, a key feature is glial cytoplasmic inclusions with accumula-
tion of -synuclein in oligodendrocytes and neurons (Papp et al.,
1989; Lantos and Papp, 1994; Spillantini and Goedert, 2000)
whilst in PSP the hallmark is accumulation of abnormally phosphory-
lated microtubule-associated tau protein () in neurons and glia
(Hauw et al., 1994; Dickson et al., 2007). Although the pathogenic
mechanisms underlying MSA and PSP are unknown, there is evi-
dence that glutamate toxicity may contribute to neuronal damage
in these and other neurodegenerative diseases (Albin and
Greenamyre, 1992; Albers and Augood, 2001; Mattson, 2003;
Przedborski, 2005). The benzothiazole drug riluzole has a number
of pharmacological effects that contribute to neuroprotection in
experimental paradigms of neurodegenerative diseases including
anti-excitotoxic activity, blocking of voltage dependent sodium-
channels, free-radical scavenging, anti-apoptotic and neurotrophic
effects and inhibition of protein aggregation (Doble, 1999; Heiser
et al., 2002; Yoo et al., 2005; Caumont et al., 2006; Shortland et al.,
2006). In a rodent model of MSA, riluzole improved some measures
of neuronal damage (Diguet et al., 2005; Scherﬂer et al., 2005).
Riluzole (up to 200mg daily) is well tolerated and prolongs
survival in amyotrophic lateral sclerosis (Bensimon et al., 1994;
Lacomblez et al., 1996; Miller et al., 2007). Thus far, riluzole remains
the only agent shown to modify disease progression in a human
neurodegenerative disorder.
In order to test the hypothesis that riluzole may slow disease
progression in PSP and MSA, we carried out a phase-III, random-
ized double-blind placebo controlled trial in 44 centres in France,
Germany and the UK. The study design incorporated ancillary
objectives including natural history, development and validation
of more sensitive diagnostic criteria and functional measures of
disease severity and progression, cognition, quality of life, health
economics, MRI changes, pathology and the establishment of
brain and DNA banks. We describe here the design and main
outcomes of the NNIPPS trial in terms of the efﬁcacy and safety
of riluzole, the psychometric validity of the NNIPPS diagnostic
criteria in relation to clinic and pathology and the major factors
inﬂuencing prognosis for PSP and MSA.
Methods
NNIPPS was designed as a double-blind placebo-controlled, stratiﬁed
(by diagnosis of MSA or PSP, and by centre), parallel group, European
(France, Germany, United Kingdom) trial assessing the efﬁcacy
and safety of riluzole at ﬂexible dose (50–200mg/day) (Fig. 1). The
primary objective of NNIPPS was to demonstrate the efﬁcacy of
riluzole on survival (primary end-point) and rate of decline in motor
function (secondary end-points).
The number of patients required was determined for the primary
end-point survival and for each stratum (PSP, MSA). Assumptions
included mean disease duration of 3 years prior to entry and no loss
to follow-up. Assuming a 41% death rate at 3 years in the placebo
group (Litvan et al., 1996a; Testa et al., 1996, 2001; Ben-Shlomo
et al., 1997; Litvan, 2003; Golbe and Ohman-Strickland, 2007;
Schrag et al., 2007), 400 patients provide over 80% power to
detect a 40% decrease in the relative risk of death in the treated
group using the log-rank test with two-sided  risk set at 0.05.
With both strata combined (800 patients), the power reached 98%
to detect a 40% decrease in the risk of death with active treatment
compared to placebo, assuming that a minimum of 272 events would
be observed over the 36-month trial period.
Patients and treatment
From consensus criteria (Litvan et al., 1996a, d, 2003) we derived
simpliﬁed operational diagnostic criteria suitable for large-scale clinical
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were deﬁned according to these operational diagnostic criteria
(Table 1). The history of the condition in each patient was evaluated
at entry using systematic questionnaires recording the initial (pre-
senting) symptom, and current syndromes (entry and last visit).
Response to levodopa therapy was evaluated at entry. Additional
assessments related to ancillary studies including a new functional
scale (the Parkinson Plus scale), magnetic resonance imaging, neuro-
psychology, health economics and quality of life, genetic testing and
neuropathology, will be presented separately.
Patients were allocated to treatment according to a computer
generated randomization list, stratiﬁed for diseases (MSA or
PSP) and clinical centre, with a riluzole to placebo ratio of 1:1.
Riluzole (50mg) or placebo was prepared as identical tablets (Sanoﬁ-
Aventis, Antony-France). Packaging and labelling (LC
2, Lentilly-France)
and treatment management (Cardinale, Corby-UK; Clindata,
Weilerswist-Germany; AGEPS-AP HP, Paris-France) was performed
so as to safeguard blinding to treatment allocation throughout
the trial duration.
Following randomization, a monthly dose-titration over 3 months
was used with increasing dosage from one, two and four tablets daily
during which time tolerance was assessed with monthly laboratory
tests for haematology (full blood count) and liver function (including
ALT and AST) and patient’s reporting of adverse events. Dose ﬂexibility
(one to four tablets per day) according to tolerance was allowed
throughout the 36-month study period, with each dose-adjustment
recorded. Study treatment withdrawal was not considered as an ‘end
of study’ and the protocol required that patients should be followed
for the ITT analysis to the end of the planned double-blind period.
Treatments were delivered to patients every 3 months and the tablets
returned were counted to evaluate compliance.
Assessments
To assess the psychometric validity (see Statistical analysis section)
of the NNIPPS operational diagnostic criteria, investigators were
required to assign at entry a diagnostic probability (PSP or MSA) for
each patient using two 100mm-visual analogue scales (VAS). These
clinical diagnostic assessments were completed at entry, every 12
months thereafter, and at the last visit. When possible, clinical diag-
nosis was compared to neuropathological diagnosis, which was
assessed blind to the clinical diagnosis at all stages of processing and
analysis of donated brains. The latter were processed according to
a standard protocol incorporating formalin ﬁxation of one hemisphere
(randomly allocated by the UK, French or German coordinating
centres) with freezing (at –80C) of the other hemisphere for banking.
Tissue sections were assessed against standard diagnostic criteria
(Lantos and Papp, 1994; Litvan et al., 1996d; Dickson, 1999) with
cross-examination and consensus scoring for each case.
The primary criterion of efﬁcacy was deﬁned as survival during
the 36-month double-blind period of the study (1095 days included)
or until the administrative cut-off date (November 30, 2004 included)
whichever came ﬁrst. The primary end-point was deﬁned as death
from any cause. All dates of death were documented with death
certiﬁcates. For all surviving patients, the date of last contact was
also documented.
Secondary end-points included standard assessments used in idio-
pathic Parkinson’s disease completed at entry and 6 monthly, using
the Hoehn and Yahr staging scale (Hoehn and Yahr, 1967), the
Schwab and England Activities of Daily Living scale (SEADL, Schwab
and England, 1969) as well as generic health scale assessments using
the Clinical Global Impression for disease severity completed by inves-
tigators (CGI-ds; Streiner and Norman, 2003) and a CGI adapted to
autonomic function assessment (CGI-dysautonomia). The Mini-Mental
State Examination (MMSE; Folstein et al., 1975) was completed by the
clinical observer at entry and every 12 months. In addition, a speciﬁc
functional measure assessing ambulation was developed (Short Motor
Disability Scale, SMDS) and performed at entry and 3 monthly
(Supplementary Table 1). Anticipated non-serious adverse events
of riluzole included dizziness, gastrointestinal symptoms, and fatigue
(Lacomblez et al., 1996). The main anticipated serious adverse
event (SAE) for riluzole was serious abnormality of liver function
tests deﬁned as ALT 45 the upper limit of normal. Safety was eval-
uated through clinical examination, vital signs, routine laboratory tests
including haematology and transaminases (AST, ALT), concomitant
medication and patient reports of adverse events (at entry and
3 monthly). Adverse events, serious and non-serious were coded
using MedDRA version 6.0 (MedDRA MSSO, Northrop Grumman
Corp., Reston, VA, USA). Weight and electrocardiogram were
assessed at entry and at the ﬁnal visit.
Statistical analysis
An Independent Data Monitoring and Safety Committee (IDMSC)
was established for unblinded review of all SAEs during the trial and
to advise the Steering Committee at regular intervals regarding con-
tinuation of the trial according to predeﬁned stopping rules. No interim
analysis for efﬁcacy was planned but four safety analyses were per-
formed throughout the study to ensure that mortality in the treated
group was not in excess compared to the placebo group.
The detailed statistical plan was submitted to the French IRB prior
to unblinding. The primary analysis was conducted following the ITT
principles. The ITT population was deﬁned as all randomized subjects
who received at least one dose of study medication and for whom
there were no major violations of GCP (ICH-6). Sensitivity analyses
population deﬁnition is described in Supplementary Text 1.
For the primary analysis, the diagnosis at inclusion was used to
deﬁne the PSP and MSA strata. In addition, the statistical plan deﬁned
Months
PSP
Riluzole  Placebo
MSA
0 1 2 3 6 9 12 15 18 21 24 27 30 33 36
Inclusion
MRI
Neuropsychology
Neurology
Dose titration
Termination
Assessments
Riluzole Placebo Randomisation
Selection
Safety
Fig. 1 Trial Flow Chart. At the selection stage, patients were
assigned to either the MSA or PSP strata according to the
NNIPPS diagnostic criteria. Following Inclusion, patients within
each stratum were randomly allocated to either the riluzole
or placebo group on 1:1 ratio and followed-up 3 monthly for
36 months in double-blind fashion. Arrows indicate the time
of each assessment.
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for the possibility of misdiagnosis.
The Safety Population comprised all randomized subjects who
received at least one dose of study medication. All analyses were
performed using SAS Software version 11. According to the guidelines
for the standard for educational and psychological testing (American
Psychological Association, 1985) two facets of the psychometric
validity of the diagnostic criteria were evaluated, the convergent and
the predictive validity. The convergent validity was assessed by the
degree of correlation between diagnostic classiﬁcation according
to inclusion criteria and the investigator’s assessment of diagnostic
probability on the VAS. As inclusion criteria represent a nominal
variable with two modalities (MSA, PSP), we used the point biserial
coefﬁcient which is the relevant method in this case (point-
biserial correlation, rpb; Nunnally and Bernstein, 1994). Predictive
criterion-related validity of the clinical diagnostic criteria was assessed
by calculating the speciﬁcity, sensitivity, percent correct classiﬁcation
and positive likelihood (Attia, 2003), using pathological diagnosis as
the gold standard.
Descriptive analyses summarized the overall population, and the
population sub-divided by treatment group, by strata (PSP versus
MSA) and by treatment within strata. Categorical data were summar-
ized by frequency and percentage. The log-linear model was used
to compare distributions between factors including treatment,
strata, country and all interactions (chi-square tests of partial associa-
tion) (Bishop et al., 1975). Continuous data were summarized
by mean and standard deviation. Between treatment groups compar-
ison at entry was carried out using three-factor variance analyses
including treatment, strata, country and all interaction factors
(Winer, 1971).
Table 1 NNIPPS Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
BOTH STRATA All of the following:
-Akinetic-rigid syndrome;
-Age at disease onset 530 years;
-Disease duration (12 months to 8 years);
-Signed informed consent.
Any of the following:
-Idiopathic Parkinson’s disease;
-Evidence of any other neurological disease
that could explain signs;
-History of repeated strokes with stepwise
progression of parkinsonian features;
-History of major stroke;
-Any history of severe or repeated head injury;
-A history of encephalitis;
-A history of neuroleptic use for a prolonged period
of time or within the past 6 months;
-Street-drug related parkinsonism;
-Signiﬁcant other neurological disease on CT-scan/MRI;
-Oculogyric crises;
-Signs of corticobasal degeneration;
-Signs of lewy body disease;
-Other life-threatening disease likely to interfere
with the main outcome measure;
-Any clinically signiﬁcant laboratory
abnormality, with the exception of cholesterol,
triglyceride and glucose;
-Renal failure (serum creatinine 4 300mM/l);
-Transaminase elevation 4 2 time upper limit of normal;
-Presence of contra-indicated treatments;
-Any previous participation in a therapeutic trial
within 3 months prior to entry;
-Patient likely to be non-compliant or not easily
reached in case of emergency;
-Patient under legal guardianship (France only).
PSP All of the following:
-Supranuclear ophthalmoplegia;
-Postural instability or falls
(within 3 years from disease onset).
Any of the following:
-Cerebellar ataxia;
-Symptomatic autonomic dysfunction;
-Tremor at rest.
MSA One or more of the following:
-Symptomatic autonomic dysfunction;
-Cerebellar ataxia;
-Postural instability or falls
(within 3 years from disease onset);
-Pyramidal signs.
Any of the following:
-Supranuclear ophthalmoplegial
-Signs of severe dementia.
According to the NNIPPPS standard operating procedures, for inclusion into the PSP stratum, supranuclear ophthalmoplegia required ‘deﬁnite slowness and/or
moderate to deﬁnite limitation of downward gaze’. For MSA, cerebellar ataxia required a moderate to severe ataxia of trunk and/or limbs. Less marked signs which
the investigator nonetheless considered clinically signiﬁcant were not considered as inclusion criteria but allowed investigators to report the presence or absence of
an oculomotor or cerebellar syndrome. The akinetic-rigid syndrome was deﬁned as mild to severe rigidity or slowness of neck or limbs. Signiﬁcant symptomatic
autonomic dysfunction (not treatment induced) was deﬁned as moderate to severe CGI-dysautonomia. A MMSE score of 420 was regarded as evidence of severe
dementia. Contraindicated treatments included glutamatergic drugs (e.g. amantadine, lamotrigine, dextrometorphan, gabapentin, glutamate containing drugs), free
radical scavengers (selegiline, vit-E/ or C at very high dose) or any drug given to treat the disease and not the symptoms; potentially hepatotoxic drugs (e.g. dantrolene);
drugs interacting with riluzole metabolism (CYP1A2 inhibitors or inducers); and ropirinole (due to decreased levels of the drug induced by riluzole).
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curves were compared using the Mantel-Cox (log-rank) test (Mantel
and Haenszel, 1958). Treatment effect was assessed with the stratiﬁed
log-rank test (p two-tailed test50.05). The Cox model (Cox, 1972)
including treatment, strata and interaction factors, was used to check
for treatment by strata (MSA, PSP) interaction.
The inﬂuence of demographic and clinical variables at entry on sur-
vival was tested with univariate and multivariate Cox proportional-
hazard analysis. Multivariate analysis used an automatic up and
down stepwise selection of variables (Allison, 1995).
Secondary end-point variables used for assessing disease progression
included the SMDS, the SEADL, the Hoehn and Yahr staging and
the CGI-ds. For each patient, repeated measurements were summar-
ized by slope of change over time using linear regression methods
(unweighted least square estimate; Wu, 1988). Comparisons of
slopes between the treatment groups were performed using three-
factor variance analyses, including strata, country, treatment and
interaction factors. Serious and non-serious adverse events were com-
pared between treatment groups with the Pearson’s chi-square test
or Fisher exact test where appropriate.
Ethics
Prior to inclusion, patients gave their informed written consent to
participate in the study. Separate consent was obtained both for
DNA sampling and for post-mortem brain tissue donation. The pro-
tocol and subsequent amendments were approved by Ethics
Committees/Institutional Review Boards of each coordinating centre
in the three participating countries. The trial was conducted according
to International standards of Good Clinical Practice-(ICH guidelines
and the Helsinki Declaration). An internal audit of the study was
carried out at the end of the trial before unblinding by an independent
auditor (Qualilab, Olivet, France) in the nine largest centres (three
in France, three in Germany and three in UK) accounting for 43%
of the overall trial population, and the primary criteria survival was
audited and appropriate documentation certiﬁed as 100% complete
over the whole study population.
Results
During the study period, April 2000 to December 2004, the
Independent Data Monitoring and Safety Committee performed
four safety analyses (last review, June 2004) with advice to con-
tinue the trial on each occasion.
Study populations
From April 2000 to July 2002, a total of 767 patients (PSP,
n=363; MSA, n=404) were recruited in 44 centres with 19 cen-
tres in France (n=320), 12 in Germany (n=243) and 13 in the UK
(n=204). Two patients never received treatment, and therefore
were excluded from all analyses. For ﬁve additional patients,
signed informed consent (n=3) or code break envelopes (n=2)
were missing and therefore these patients were excluded from
the ITT population (All, n=760; PSP, n=362; MSA, n=398) but
remained in the safety population analysis (n=765) (Fig. 2). The
mean daily dose on treatment in ITT population was 3.6 tablets
(180mg riluzole or placebo), and overall mean compliance was
GCP violation [5] 
Never treated [2]
Protocol violation [16] 
Treatment withdrawal [190] 
Placebo [95]    Riluzole [95] 
excluded 
excluded 
censored 
Primary
Efficacy
Analysis
Sensitivity 
Efficacy
Analyses
Primary
Safety
Analysis
OVERALL RANDOMISED [767] 
PSP [363]       MSA [404] 
Placebo   Riluzole         Placebo Riluzole
[182] [181] [201] [203]
SAFETY POPULATION [765] 
PSP  [363]       MSA [402] 
Placebo   Riluzole     Placebo   Riluzole 
[182] [181] [201] [201]
ITT POPULATION [760]
PSP [362]       MSA [398] 
Placebo
[181]
  Riluzole        Placebo Riluzole
[181] [199] [199]
PP POPULATION [744] 
PSP [353]       MSA [391] 
Placebo
[176]
  Riluzole     Placebo Riluzole
[177] [197] [194]
PPPT POPULATION [744] 
PSP [353]       MSA [391] 
Placebo   Riluzole     Placebo Riluzole
[176] [177] [197] [194]
excluded 
Fig. 2 NNIPPS populations in analyses.
160 | Brain 2009: 132; 156–171 G. Bensimon et al.81.2%  31.5. In the riluzole group, the maximum tolerated dose
of riluzole for the 284 (75%) patients who did not stop study
treatment until death or study cut-off was 200mg in 237 patients
(83.4%), 150mg in 7 patients (2.5%), 100mg in 25 patients
(8.8%) and 50mg in 15 patients (5.3%).
The sensitivity analysis population is described in Supplementary
Text 1.
Effect of riluzole in patients with
PSP and MSA
Treatments were well balanced in the overall population and
within strata. There was no signiﬁcant difference between treat-
ment groups in terms of demographic features, disease severity,
previous medical history or concomitant disease at entry in the
overall population or within strata (Table 2).
Follow-up at cut-off date was complete and documented in
all patients regardless of treatment compliance except for three
patients, two of whom withdrew consent in order to be included
in another trial and one who underwent medically assisted suicide.
At the cut-off date, the surviving patients had a mean (SD)
follow-up time from randomization of 105588 days with
81.1% having completed 3 years double-blind follow-up (1095
days). Overall 140 patients (placebo n=71, riluzole n=72) had
less then 3 years follow-up at the administrative cut-off date,
and three had to be censored at the time they withdrew from
the study, as mentioned above. The mean time in study for
these 143 patients (18.8%) was 979.4117.4 days (placebo:
970.5127.3 days; riluzole: 988.2106.9 days).
Overall 342 patients (45.0%) died during the double-blind
period, with no difference between the PSP and the MSA strata
[PSP, n=171 (47.2%); MSA, n=171 (43.0%); P=0.21 by the
log-rank test]. With the strata combined, Kaplan–Meier survival
estimates at 36 months for riluzole and placebo groups were
52.6% and 54.9%, respectively. Comparison of survival curves
in treatment groups showed no statistically signiﬁcant difference
either in the overall population (P=0.42 by the stratiﬁed log-
rank test) or within strata (Kaplan–Meier estimates for PSP-
riluzole: 0.51, PSP-placebo: 0.50; and for MSA-riluzole: 0.53,
MSA-placebo: 0.58; P=0.66 and P=0.48 by the log-rank test,
respectively) (Fig. 3). Accordingly there was no statistically signi-
ﬁcant treatment by strata interaction (P=0.85, by a Cox model
analysis).
For secondary efﬁcacy end-points of disease progression, 651
patients (86%) had at least two assessments allowing calculation
of a slope of change in scores for Hoehn and Yahr Staging, SEADL
and CGI for severity. For SMDS 714 (94%) patients had usable
data for calculating slope of change. All scales showed high sensi-
tivity to change with time (P50.0001). Strata differences were
evident with the SEADL, CGI for severity and SMDS (P=0.003,
P=0.0003, P=0.03, respectively; Table 3), with the PSP group
showing more rapid progression compared to the MSA group.
As with the primary end-point, there was no statistically signiﬁ-
cant difference between treatment groups in progression rate with
any of the scales, either in the overall population or within strata.
The PPPT analysis showed identical results for primary and sec-
ondary end-points (data not shown).
To test our initial assumptions, using the data acquired during
the study, we calculated the detectable difference in survival and
functional change. With power greater than 0.8, and  risk at 0.05
(two-tailed), the actual number of patients recruited and events
observed would have allowed us to detect a 40% decrease in
relative risk of death for PSP and 35% for MSA, consistent with
our initial hypothesis. For functional change, using the SEADL as
the most sensitive scale, we would have been able to detect diff-
erences in annual rate of progression of 32% for PSP and 36%
for MSA.
Table 2 ITT population characteristics at entry
Placebo Riluzole
PSP, n=181 MSA, n=199 PSP, n=181 MSA, n=199
Sex
Female (%) 40.3 44.2 44.8 46.2
Age at entry (years)
 67.77.0 62.68.1 68.06.6 61.98.5
Age at onset (years)
 63.87.0 58.28.3 63.97.0 57.38.6
Disease duration (years)
 3.91.9 4.42 4.11.9 4.51.9
Short Motor Disability Scale (0–17) 6.43.7 6.13.9 6.73.6 6.13.6
Frontal Assessment Battery (0–18)
 11.14.3 14.63.2 11.34.1 14.33.3
Mini-Mental Status Examination (0–30)
 25.44.4 27.82.3 25.24.4 27.62.5
Schwab & England Activity Daily Living (0–100)
 50.224.5
a 53.824.8 48.323.6 53.324.3
Hoehn and Yahr Staging (0–5)
 3.61.0 3.41.0 3.60.9 3.51.0
Clinician Global Impression Disease severity (0–6)
 3.61.0 3.61.0 3.71.0 3.60.9
Clinician Global Impression Dysautonomia (0–3)
 0.60.6 1.80.8 0.60.6 1.80.8
Quantitative variables were analysed using variance analysis and categorical data using a log-linear model. Factors included in models were strata, treatment, country
and strata by treatment interactions. Signiﬁcance was set at P50.05 (two-tailed test) for each factor or interaction. No differences related to treatment group were
detected at entry for the whole population or within strata.
All values are mean  SD.
a n=180 due to one missing value.
 Differences between PSP and MSA strata (P50.05; two-tailed test) were found for all variables except for sex and the Short Motor Disability Scale score.
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Analysis of all SAEs revealed no signiﬁcant differences between
riluzole and placebo groups for the frequency of unexpected
SAEs. However, for expected SAEs (other than death) with fre-
quency of greater than 5%, gastrointestinal events were more
common with riluzole treatment (Table 4). Borderline signiﬁcant
differences were observed in SAEs with frequency below 5%.
Cardiac disorders were more common in the riluzole group
(2.6% versus 0.8% placebo) and urinary disorders more frequent
in the placebo group (4.4% versus 1.8% riluzole). With all treat-
ment groups combined, there were signiﬁcant differences between
PSP and MSA, with injuries due to falls more common in PSP
(18% versus 8% in MSA) and gastrointestinal disorders related
to dysphagia more frequent in PSP (11% versus 6%). Events
related to death are given in Table 4. The main causes were related
to respiratory disorders, general condition (terminal state) and
infections (urinary or pulmonary). Gastrointestinal complications
were more common in PSP (4% versus 1% for MSA). Among
the non-serious events, gastrointestinal disorders were again
more common with riluzole (34% versus 27% with placebo,
P=0.03). The frequency of vascular disorders (mainly haematoma
related to falls) was also slightly higher in the riluzole group (13%
versus 8% with placebo, P=0.02). Elevation of transaminases
was rare, with values above three times normal reported for only
11 patients on riluzole (3%) and eight patients on placebo (2%).
Validity of NNIPPS diagnostic criteria
At entry, the investigators’ assessments of diagnostic probability
for PSP or MSA were in close agreement with the inclusion cate-
gory (point-biserial correlation for MSA rpb=0.93, P50.0001, and
for PSP rpb = 0.95, P50.0001) demonstrating an excellent con-
vergent validity. For a few patients, the VAS probability was equal
PSP (N=362) – ITT Population
 
Patients at risk 
Placebo 181  176  161  146  128  107  63 
Riluzole 181  166  151  139  122  93  65 
Patients death/censored 
Placebo 0/0  5/0  20/0  35/0  53/0  67/7  85/33 
Riluzole  0/0 15/0  30/0 42/0  59/0 79/9  86/30 
MSA (N=398) – ITT Population
 
Patients at risk 
Placebo 199  187  172  158  141  123  90
Riluzole 199  190  176  158  143  121  85
Patients death/censored 
Placebo  0/0  12/0 26/1 39/2  56/2  70/6  81/28
Riluzole  0/0  9/0  23/0  40/1  55/1  72/6  90/24
Fig. 3 Kaplan–Meier survival curves of riluzole and placebo groups in PSP and MSA strata.
Table 3 Slope of change in functional measures
Placebo Riluzole
PSP, n=181 MSA, n=199 PSP, n=181 MSA, n=199
Short Motor Disability Scale
 3.14.4 (171) 2.32.7 (190) 3.04.0 (168) 2.72.9 (185)
Schwab and England Activity Daily Living
 16.317 .5 (162) 11.512.4 (172) 15.214.1 (149) 12.916.5 (168)
Hoehn and Yahr Staging 0.50.8 (162) 0.50.6 (172) 0.60.7 (149) 0.50.8 (168)
Clinical Global Impression of disease severity
 0.70.7 (162) 0.50.6 (171) 0.70.8 (148) 0.50.8 (168)
Slope of change for each patient was calculated using simple linear regression method of dependent variable with time since randomization. Patient with at least
two measures in study were included in analyses. Slope of change in functional scale scores are shown as mean points/year  SD with numbers of patients in
each analysis in parentheses. No statistically signiﬁcant difference between treatment groups could be evidenced in either scale.
 Strata differences were observed with the SEADL (P=0.003), CGI disease severity (P=0.0003) and SMDS (P=0.03).
162 | Brain 2009: 132; 156–171 G. Bensimon et al.for PSP and MSA (Fig. 4). Overall, diagnostic conﬁdence (VAS
probability of each diagnosis) was signiﬁcantly higher (Student’s
t-test 2.89, P=0.004) for PSP patients [mean 81.2, SD12.8
(range 0.40–1)] than for MSA patients [mean 78.4, SD14.1
(range 0.21–1)].
A total of 210 patients (27%) consented to brain donation.
Analysis of 112 brains was completed at the time of writing.
Comparisons of patients with a pathological diagnosis with
those dying without pathological studies showed no difference
in demographic characteristics, disease severity at entry or diag-
nostic probability (data not shown).
Histopathology showed that the NNIPPS clinical diagnostic
criteria had correctly identiﬁed Parkinson plus syndromes in 94%
of cases. Two patients with pathologically conﬁrmed MSA were
mis-stratiﬁed at entry as PSP, and three with pathologically con-
ﬁrmed PSP had been mis-stratiﬁed as MSA (overall 4.9% mis-
stratiﬁcation). For the PSP stratum, seven cases were found to
have other conditions, including two with Lewy body disease,
one with amyotrophic lateral sclerosis (ALS), one with basophilic
inclusion body disease, and three with corticobasal degeneration
(CBD). In the MSA stratum, there were three misdiagnoses includ-
ing one case with Lewy body disease, one with ALS and one
with non-speciﬁc lesions. The sensitivity (95% CI) and speciﬁcity
(95% CI) of the NNIPPS clinical diagnostic criteria for MSA were
0.96 (0.88–0.99) and 0.91 (0.86–0.93) respectively, with a correct
clinical diagnosis in 0.93 (0.87–0.96) of cases and positive like-
lihood of 10.67 (6.28–14.39) (Table 5). For patients diagnosed
clinically as PSP, but excluding cases diagnosed pathologically as
CBD, sensitivity (95% CI) and speciﬁcity (95% CI) of clinical
diagnostic criteria were 0.95 (0.89–0.98) and 0.84 (0.77–0.87)
respectively, with 0.89 (0.83–0.93) having a correct clinical diag-
nosis and positive likelihood of 5.79 (3.79–7.58). These results
are evidence of an excellent predictive validity of the NNIPPS
diagnostic criteria. This was not explained by the higher than
expected disease severity and thus the large number of late
stage patients in the overall population. We conducted the same
analysis on the population broken down by severity according
to the median of the CGI-ds at baseline, which was identical
in the overall population and in the sub-group with neuropathol-
ogy diagnosis. Mean  SD CGI-ds was 2.60.5 and 2.90.3
in early patients with PSP and MSA, respectively, and 4.50.6
and 4.50.7 in late patients with PSP and MSA, respectively.
As shown in Table 5, results in early patients were not sig-
niﬁcantly different from those in late patients demonstrating
a good consistency of the parameters with regard to disease
progression. All three CBD cases fell within the late stage cate-
gory. When CBD was included in the PSP neuropathology
cases, there was slightly but not signiﬁcantly increased diagnostic
speciﬁcity, overall fraction correct, and positive likelihood for
the overall sample and the late disease patients subgroup (data
not shown).
Reassessment of the clinical diagnosis was achieved at least
once during the trial period in 554 (73%) patients who did not
have a neuropathological diagnosis (PSP, 71%; MSA, 75%). The
overall rate of change in clinical diagnosis after entry was 7%,
(Table 6), consistent with the neuropathological ﬁndings.
Table 4 Serious Adverse Events—MedDRA classiﬁcation (By System Organ Class)
System Organ Class, n (%) Related to death Related to hospitalisation
Placebo N=383 Riluzole N=382 Placebo N=383 Riluzole N=382
Respiratory, thoracic and mediastinal disorders 60 (25) 65 (29) 33 (14) 40 (12)
General disorders and administration site conditions 56 (24) 56 (25) 27 (12) 39 (12)
Infections and infestations 37 (16) 49 (22) 38 (16) 50 (15)
Cardiac disorders 25 (11) 14 (6) 3
a (1) 10 (3)
Surgical and medical procedures 13 (6) 8 (4) 13 (6) 19 (6)
Gastrointestinal disorders 13 (6) 7 (3) 23
a (10) 41 (13)
Nervous system disorders 12 (5) 7 (3) 22 (9) 25 (8)
Metabolism and nutrition disorders 3 (1) 6 (3) 10 (4) 8 (2)
Injury, poisoning and procedural complications 6 (3) 2 (1) 48 (20) 49 (15)
Neoplasms benign, malignant and unspeciﬁed 5 (2) 2 (1 2 (1) 2 (1)
Psychiatric disorders 2 (1) 4 (2) 13 (6) 19 (6)
Skin and subcutaneous tissue disorders 3 (1) 1 (0.4) 3 (1) 1 (0.3)
Vascular disorders – 3 (1) 7 (3) 8 (2)
Renal and urinary disorders 2 (1) – 17
a (7) 7 (2)
Reproductive system and breast disorders 1 (0.4) – 3 (1) 1 (0.3)
Hepatobiliary disorders – – 3 (1) 3 (1)
Investigations – – 5 (2) 1 (0.3)
Musculoskeletal and connective tissue disorders – – 3 (1) 3 (1)
Blood and lymphatic system disorders – – 3 (1) –
Eye disorders – – 2 (1) –
Ear and labyrinth disorders – – – 1 (0.3)
Total events 238 224 235 327
Total patients, Number of events (percentage of patients) 169 (44) 176 (46) 145 (38) 164 (43)
a Statistically signiﬁcant difference between treatment by the Fischer exact test.
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of the NNIPPS cohort
Analysis of the systematic questionnaire on initial clinical signs
showed that the akinetic-rigid syndrome (with or without falls)
was a frequent presenting syndrome in the PSP stratum (70.2%)
and in the MSA stratum (61.8%). In the PSP stratum, oculomotor
abnormalities were an initial feature in only 7.7% of patients,
while 11.0% had presented with a behavioural or cognitive syn-
drome, and 5.8% had bulbar or pseudo-bulbar features. In MSA,
second to akinetic-rigid syndrome, the most common presenting
clinical features were cerebellar (22.1%) and genito-urinary
(9.1%). The date of onset of gait instability or falls was
documented in 93.3% of the population (92.5% PSP, 94.0%
MSA). Falls within the ﬁrst year of disease onset, as incorporated
in the NINDS-SPSP criteria (Litvan et al., 2003) were present in
only 49.6% of the PSP patients, and were also present in 21.9%
of the MSA group. Similar results were observed in neuropatho-
logically conﬁrmed cases (PSP 53.6%, MSA 27.9%). A similar
proportion of patients in the PSP and MSA strata had levodopa
therapy at entry [PSP, n=307 (85%); MSA, n=334 (84%)],
although the mean daily dose of levodopa was higher in the
MSA group (636mg/day, range 50–2100mg) compared to the
PSP group (509mg/day, range 50–1600mg) (P50.0001)
(Supplementary Table 2). Overall, most patients had a very poor
response to levodopa therapy. A greater than 50% response
to levodopa was reported for only 1.5% of MSA patients, and
none of the PSP group. A best-ever response to levodopa therapy
450% was reported more frequently for MSA patients (9.1%)
than for PSP patients (2.6%) (P=0.0002). In the majority of
those who had experienced a good response to levodopa, the
duration of response was 51 year.
At time of entry in the study, the distribution of the various
syndromes is given for both diagnostic categories (Fig. 5).
Oculomotor abnormalities were present in all PSP patients
except one, but were also noted in 19% of MSA patients. PSP
patients showed a higher rate of cognitive and behavioural
syndromes. Dysautonomia was present in the majority of MSA
patients, with urinary symptoms (87%) more common than car-
diovascular symptoms (57%). Urinary symptoms were also
present in 48% of PSP patients. A cerebellar syndrome was
reported in 50% of MSA cases, but also a small number of PSP
patients (6%). Pyramidal signs were present in approximately
half the cases, slightly more in the MSA strata. A high frequency
of bulbar/pseudobulbar features was reported in the MSA patients
group (63%) and the PSP group (76%).
There were no differences between disease strata in terms of
gender, weight or height. MSA patients were younger than the
PSP patients at entry, younger at disease onset and had longer
disease duration prior to entry (Table 2). Assessments of disease
severity by the CGI-ds or the modiﬁed Hoehn and Yahr staging,
showed there were signiﬁcantly fewer MSA patients in the most
severe stage (P=0.024 and P=0.048). Likewise, strata difference
in scores for the SEADL indicated less dependency for MSA than
for the PSP patients (P=0.017). As expected, PSP patients scored
worse on cognitive functions as assessed with the MMSE
(P=0.0001) (Table 2).
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Fig. 4 Convergent validity of NNIPPS Diagnostic Criteria with
Investigators’ Diagnostic Probability (VAS). At the inclusion
visit, following patients’ assignment to strata using the NNIPPS
diagnostic criteria, investigators were asked to evaluate the
probability of each diagnosis (PSP, MSA), using a 100mm VAS.
All 760 patients are plotted on the graph according to
the probability score on each VAS (PSP-vertical axis, MSA-
horizontal axis). Solid diamonds represent patients included
in the PSP stratum; White circles represent patients included in
the MSA stratum. Convergent validity of the NNIPPS inclusion
criteria with the investigators’ assessment of diagnostic prob-
ability was tested with the point-biserial correlation. MSA,
rpb=0.93 (P50.0001), PSP, rpb = 0.95, (P50.0001).
Table 5 Predictive validity of NNIPPS clinical diagnostic criteria in deceased patients with neuropathological diagnosis
CGI54 n=39 CGI54 n=73 ALL n=112
PSP MSA PSP MSA PSP MSA
Sensitivity (95% CI) 0.95 (0.82–0.99)0.88 (0.73–0.95) 0.95 (0.86–0.98) 1.0 (0.91–1) 0.95 (0.88–0.98) 0.96 (0.88–0.99)
Speciﬁcity (95% CI) 0.84 (0.7–0.89) 0.91 (0.79–0.96) 0.83 (0.74–0.87) 0.91 (0.86–0.91) 0.84 (0.77–0.87) 0.91 (0.86–0.93)
Overall fraction correct (95% CI)0.90 (0.77–0.94)0.90 (0.77–0.96) 0.89 (0.80–0.93) 0.95 (0.88–0.95) 0.89 (0.83–0.93) 0.93 (0.87–0.96)
Positive likelihood (95% CI) 6.01 (2.83–8.60)9.71 (3.50–26.48)5.68 (3.35–7.71)11.25 (6.32–11.25)5.79 (3.79–7.58)10.67 (6.28–14.39)
Sensitivity, speciﬁcity, overall fraction correct and positive likelihood (95% CI) of NNIPPS diagnostic criteria in the overall population with neuropathology diagnosis, and
broken down by disease severity as deﬁned by the CGI. Early patients were deﬁned as those below the median (CGI, range 1–3); late patients were those equal or over
the median (CGI, range 4–6).
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assessed with univariate and multivariate Cox model analysis
(Supplementary material and Supplementary Table 7). In the uni-
variate analyses, only variables scoring disease severity were
predictive of survival. Accordingly, the stepwise multivariate
analysis selected ﬁrst the SEADL, followed by the CGI scales for
disease severity and for dysautonomia, as strong predictors of
survival.
However, following adjustment on these variables, disease dura-
tion was selected in the model (RR = 0.923, P=0.007) indicating
that at constant severity patients with a shorter disease duration
at entry had a worse prognosis (‘fast progressors’). To visualise the
discriminating accuracy of the combined variables, we constructed
a prognostic score for each patient using a Cox coefﬁcient
weighted linear combination of the selected prognostic variables
(Supplementary Fig. 1A). Following adjustment on the prognostic
score as a variable, the strata factor became signiﬁcant (RR =
0.657, P=0.0002) indicating that PSP patients on the whole had
a worse prognosis compared to MSA patients at constant disease
severity and disease duration at entry (Supplementary Fig. 1B).
Testing for a treatment effect on survival following adjustment
on the prognostic variables did not change the results of the
log-rank analysis nor was there any signiﬁcant interaction between
treatment and prognostic variables (Supplementary Table 3).
Discussion
Our results show that riluzole (up to 200mg/day) is unlikely to
be effective as a disease-modifying agent in PSP or MSA. Riluzole
has a deﬁnite effect in ALS with an estimated 30–40% decrease in
relative risk at 12–18 months (Bensimon et al., 1994; Lacomblez
et al., 1996; Miller et al., 2007). NNIPPS was therefore designed
to detect an effect of similar size. Power calculation assumptions
for the placebo group were based largely on retrospective data
(Litvan et al., 1996a, c, 2003; Testa et al., 1996, 2001; Ben-
Shlomo et al., 1997), which underestimated the number of
events observed in NNIPPS by 2–6%. Hence the NNIPPS trial
achieved the power necessary to detect the hypothesized drug
effect. The failure of NNIPPS to detect that effect could be
due to heterogeneity in the trial population (loss of power),
uneven distribution of demographic and clinical prognostic factors
or comorbidity across treatment groups (randomization bias), poor
compliance, or simply a smaller pharmacological effect in these
conditions than the one used at the planning stage (effect size).
With regard to disease heterogeneity, a major difﬁculty in
designing trials of disease-modifying therapy in neurodegenerative
diseases is lack of diagnostic conﬁdence, particularly at a stage
of disease evolution when intervention is likely to be most effec-
tive. Indeed, there are no prospective studies of clinical diagnostic
criteria assessed against the deﬁnitive criterion of histopathology
in PSP or MSA (Litvan et al., 2003). Such studies are not easy
to achieve, as long term follow-up and a high autopsy rate are
required. Until validated biomarkers are available for use in trials,
clinical criteria prospectively tested against pathology are essential
to understand heterogeneity, which is a potential source of bias
in estimating drug effects in Parkinson plus syndromes, as in idio-
pathic Parkinson’s disease. Furthermore, criteria for large scale
clinical trials in rare diseases such as PSP and MSA should be
robust and simple, so that they can be applied in international
multi-centre studies and not only in highly specialized centres.
The NNIPPS diagnostic criteria represent a simpliﬁcation of existing
diagnostic criteria and we have shown them to have excellent
convergent and predictive validities in this study population,
Table 6 Change in clinical diagnosis during the trial showing predictive validity of NNIPPS clinical diagnostic criteria in
surviving patients
Clinical diagnosis at inclusion Final clinical diagnosis All
PSP MSA Other

PSP 246 (96%) 2 (1%) 8 (3%) 256
MSA 13 (4%) 270 (91%) 15 (5%) 298
All 259 272 23 554
 Other diagnosis: MSA (N=15): IPD n=7, ALS n=2, CBD n=3, LBD n=1, Carbon dioxide intox n=1, MPI multilacunar n=1; PSP (N=8): Mixed PSP/MSA n=1,
Lower body Parkinsonism – pseudo PSP n=1, CBD n=1, FTDP or Motor neuron disease n=1, ophthalmoplegia n=1, FTD n=1, multiple cerebral infarct n=1,
unidentiﬁed n=1.
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Fig. 5 Syndrome proﬁle of patients in PSP and MSA Strata.
At the inclusion visit, and based on the clinical neurological
assessments, investigators were asked to describe the syndrome
proﬁle of the patients using a systematic (yes/no) question-
naire. Each bar represents the percentage of patients within
each stratum positive for a given syndrome. Black bars
represent the MSA stratum, grey bars the PSP stratum. The
akinetic rigid syndrome was a mandatory inclusion criterion
for both strata and therefore is not represented.
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44 centres. Although pathological examination was only possible
in 112 cases (15% of recruited patients), the pathological sample
is representative of those patients who died (45%) and, most
likely, of the population as a whole. Further analysis of these
diagnostic criteria in relation to MRI, DNA and neuropsychology
is ongoing. At this stage it can be concluded that the estimated
rate of misdiagnosis (about 6% overall, representing at most 46
patients in the ITT) is acceptably low and is unlikely to have biased
the estimate of the drug effect. We could not detect imbalance
in entry parameters with relevant prognostic signiﬁcance for
survival or disease progression which could account for the lack
of treatment efﬁcacy.
It is likely that a neuroprotective agent should be started in
the earliest phase of the disease in order to demonstrate efﬁcacy.
Hence the impact of a neuroprotective agent is likely to be an
inverse function of the stage of disease progression. In support of
this assumption, riluzole did not show efﬁcacy in ALS when tested
in a trial including late stage disease patients (Bensimon et al.,
2002). In the present trial, disease severity in the population
included was greater than anticipated and the death rate was
also higher than expected. Overall, about 50% of patients were
classiﬁed as severely disabled or wheelchair bound (i.e. in the
latest stages) by the Hoehn and Yahr staging and over 50% simi-
larly classiﬁed as markedly, severely or extremely ill by the CGI
scale for disease severity. However, adjustment for prognostic
factors with the Cox model did not show any trend for a treat-
ment effect, nor was there a signiﬁcant treatment by prognostic
factor interaction, meaning that the treatment effect is constant
across the levels of the prognostic variables.
Even though treatment withdrawal rate was relatively high
(25%), and might have had an impact on the size of a treatment
effect, the overall mean dose was close to the maximum, and
compliance rate was good (81.2%) considering the length of the
trial, with a mean follow-up time close to the maximum planned
(3 years). Finally, the PPPT sensitivity analysis was consistent
with the ITT. Hence, the observed lack of treatment effect
in this Parkinson plus population seems relatively robust. Our
results are similar to those observed in Huntington’s disease
(Landwehrmeyer et al., 2007) and contrast with the ﬁndings in
ALS. This may indicate that the disease pathways targeted by
riluzole in ALS are more speciﬁc than previously thought.
At the time of designing the NNIPPS study there were no
validated instruments for measuring change in function in these
disorders. Since the priority was to detect a disease-modifying
effect of riluzole, we chose to use survival as a robust and
unambiguous endpoint for the primary analysis. There are several
reasons why prospectively acquired information on survival pro-
vides a unique tool for understanding these diseases and for devel-
oping new assessment instruments for clinical trials. First, it is
possible to achieve complete ascertainment of the endpoint, as
we have shown. Secondly, the high rate of death in PSP and
MSA limits the use of functional scales as measurements of disease
progression. Inevitably, the extent of missing functional data is
not random, so that in case of drug toxicity increasing death
rate, the remaining functional data in the active drug group is
misleading as regards efﬁcacy (Wu, 1988; Wu and Bailey, 1988)
because they originate from selection of a biased sub-group. In
early patients, when the likelihood of informative censoring is
least, slope of change in functional measures might be appropriate
as an end point in a deﬁnitive phase III trial where using survival
as an endpoint would result in substantially increasing the number
of patients and/or length of the trial. The parameters provided in
this article allow power calculations for either context since linear-
ity is a basic assumption for slope of change and should hold true
early or late in the course of disease.
Third, survival data provide a unique insight into the natural
history of these disorders and help to validate functional assess-
ments in relation to prognosis. In this study, the median survival
from onset of symptoms is in keeping with our prior assumptions
based on retrospective (Litvan et al., 1996d; Testa et al., 1996,
2001; Vanacore et al., 2001a, b; Litvan et al., 2003) and prospec-
tive studies (Schrag et al., 2008). Following a step-wise Cox model
adjustment on prognostic factors which selected disease severity
scores (SEADL, CGI-ds, CGI-dysautonomia) and disease duration,
there was a signiﬁcant difference between strata consistent with
the difference in the rate of disease progression between the two
strata. Finally, our data show that it is feasible to use survival as
a primary endpoint in phase III studies and that our strategy of
recruiting patients with PSP and MSA into a single stratiﬁed trial
is methodologically valid where a generic neuroprotective effect is
hypothesied. On the other hand, where the agent to be tested is
thought to act on disease-speciﬁc pathways (e.g. processing of tau
in PSP, or alpha-synuclein in MSA) a different strategy is likely to
be more appropriate. The demographic features of the NNIPPS
cohort clearly indicate that patients presenting with an akinetic-
rigid syndrome and categorized as having PSP or MSA with
reasonably high conﬁdence have very poor prognosis, and no
signiﬁcant response to levodopa therapy. Unfortunately, there
are no comparable prospective studies with which to compare
our cohort. The European MSA Study Group (EMSA-SG) has
reported preliminary data on a functional scale developed for
MSA based on assessments of 50 patients diagnosed on the
basis of the Gilman criteria (Gilman et al., 1998). A total of 412
patients with presumed MSA were included in a European registry
(Geser et al., 2005, 2006), but no information on survival is yet
available from the EMSA database. Nevertheless, demographic
features of the 50 patients reported from the EMSA are broadly
comparable to those in the NNIPPS MSA stratum (Geser et al.,
2006). In a cohort study of 162 PSP patients the median survival
since disease onset was 7.3 years, compared to 7.8 years in the
NNIPPS cohort (Golbe and Ohman-Strickland, 2007). As with
NNIPPS, functional scores predicted survival. However, multivari-
ate analysis of prognostic factors revealed that age of onset and
gender were predictors of survival. For the former, the apparent
discrepancy is likely to be related to differences in the method
of survival analysis since when survival is calculated from disease
onset in our cohort, age of onset becomes a signiﬁcant predictor
of survival as well (data not shown). In relation to a gender effect,
the sex ratio in most studies, as in the NNIPPS cohort, shows
an equal proportion of men and women or a slight excess of
men (Golbe et al., 1988; Santacruz et al., 1998; Schrag et al.,
1999; Nath et al., 2001, 2003), whereas in the study of Golbe and
Ohman-Strickland (2007) the sex ratio was reversed, indicating
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such as age of onset and sex ratio are similar in the NNIPPS cohort
to those recorded in previous natural history studies (Bower et al.,
1997; Schrag et al., 1999; Vanacore et al., 2001a, b; Schrag et al.,
2008).
In order to achieve a relatively homogeneous population of
patients in the PSP strata, ocumomotor abnormalities were
mandatory at inclusion. This increased the accuracy of diagnosis
(as conﬁrmed pathologically) but did not take into account ‘PSP-
Parkinsonism’ patients without oculomotor abnormalities (Williams
et al., 2005, 2007) who may be confused with patients with PD
or with MSA-P. Likewise, in order to recruit MSA patients
with relatively early disease, we took a pragmatic approach so
as to avoid, as far as possible, recruiting patients with disorders
such as olivopontocerebellar atrophy (Berciano et al., 2006) and
idiopathic late-onset cerebellar ataxia, (Gilman and Quinn, 1996;
Gilman et al., 2000). We expected this to reduce the proportion
of patients with the cerebellar form of MSA (MSA-C) in our
cohort, but cerebellar features were noted at presentation in
20% of our patients, similar to the ﬁndings of a prospective
study (Schrag et al., 2008). Thus the NNIPPS population is reason-
ably representative of the whole (European and North American)
MSA population. In this context, we have clearly shown that
clinical features that have been regarded as characteristic of
each disorder, and which are of key importance in the different
consensus diagnostic criteria (Litvan et al., 1996a, b, d, 1997,
2003; Gilman et al., 1998) are common to both disorders. Thus
at entry urinary symptoms were present in over 85% of patients
in the MSA stratum but also in 50% in the PSP stratum (Fig. 5)
and oculomotor signs, required for inclusion in the PSP stratum,
were recorded in about 20% of patients in the MSA stratum.
However, this included any evidence of supranuclear ophthalmo-
plegia, whereas allocation to the PSP stratum required signiﬁcant
supranuclear impairment of downward gaze. Likewise, behavioural
and cognitive abnormalities were judged as being common in
both PSP and MSA, in keeping with studies on cognitive function
in these disorders (Robbins et al., 1992, 1994; Burk et al., 2006;
Lyoo et al., 2008). Despite this overlap, we have shown that PSP
and MSA can be differentiated by neurologists at a relatively early
stage in the disease process using the NNIPPS diagnostic criteria.
A striking feature of the NNIPPS diagnostic criteria is the high
sensitivity at inclusion, although a direct comparison with pub-
lished diagnostic criteria is not possible as the timing of assess-
ments was different (Osaki et al., 2002, 2004; Litvan et al., 2003).
The NNIPPS diagnostic assessments were carried out on average
2 years before death in the pathologically conﬁrmed cases
whereas in the published criteria the assessments were made at
the ﬁrst (‘diagnostic’) visit when sensitivity is low, and at the
end of the disease (i.e., on the last visit before death) when sen-
sitivity is high. Studies of the sensitivity of the NNIPPS criteria
at the earliest stages of disease process are now needed, though
we provide evidence that the criteria still display acceptable quality
in the sub-group below the mid-range of disease progression.
Indeed, only because we studied both conditions in one cohort
could we discern the close similarities and the diagnostically impor-
tant differences between PSP and MSA.
We have shown that a large scale randomized trial with survival
as the primary endpoint is feasible using the Parkinson plus con-
cept to allow relatively early diagnosis and recruitment of a sur-
prisingly homogeneous population, as shown by the performance
of the NNIPPS diagnostic criteria informed by pathology. The rate
of death was higher than anticipated, allowing us to shorten the
trial slightly. We have learnt from clinical trials in ALS that survival
does not necessarily equate with functional change (Lacomblez
et al., 1996; Meininger, 2005). This has resulted in recommenda-
tions by the regulatory authorities (e.g. European Medicines
Agency, Committee for Proprietary Medicinal Products, CPMP/
EWP/565/98) and by the World Federation of Neurology
Committee on Research (Miller et al., 1999) that survival should
be the primary endpoint for deﬁnitive demonstration of a neuro-
protective drug effect. Future phase III studies on potential neu-
roprotective agents in these disorders should consider using
survival as a primary endpoint, and combining patients with pre-
sumed PSP and MSA in the same trial in order to improve our
understanding of both.
Supplementary material
Supplementary material is available at Brain online.
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